



Ambri Limited (ABN 60 079 201 835)
126 Greville St Chatswood NSW 2067 Australia
Telephone: +61 2 9422 3000 Facsimile: + 61 2 9422 3013

7 September 2004

ASX Announcement

Ambri Announces Update on Collaboration Program and Significant Improvements to the ICS™ Technology

Sydney based Ambri Limited, (ASX: ABI) today announced that its international strategic alliance partner Biosensor Enterprises LLC ("BEL"), a joint venture of Dow Corning Corporation and Genencor International, has demonstrated significant improvements to the ICS™ Technology.

Genencor scientists in Palo Alto, California, working in collaboration with Ambri scientists, have successfully demonstrated improvements for the storage of ICS™ membrane technology. This activity has been carried out as a research/technology improvement project to address specific marketing requirements that exist in the consumer environment. These improvements have not, at this stage, been included into the Ambri SensiDx™ Cartridge.

Mr Dave Cornelius, Executive Director New Ventures – Dow Corning stated "This was an important step towards the commercial viability of the Ambri ICS™ Technology in consumer applications." BEL believes Ambri's ICS™ Technology has considerable potential in consumer markets. "The collaborative efforts continue to focus on enhancements of the ICS™ Technology as well as novel new array formats for the ICS™ Technology" added Mr Cornelius.

Genencor and Ambri scientists continue to intensify their interaction to accelerate the development of the ICS™ Technology. A joint development and commercialisation meeting was recently held at Genencor. This meeting covered the technical achievements over the last 12 months and outlined a joint development plan for the ensuing 12 month period.

"BEL's improvements of the ICS™ Technology will have positive ramifications for Ambri" said Ambri's CEO, Dr Jonathan Wright. "As an alliance partner of BEL, Ambri has access to development improvements that BEL achieves. The outcome of this project clearly demonstrates that the collaboration is working in a real and meaningful way" he added.

For further information contact:
Jonathan Wright, Managing Director/CEO
Jeff Carter, Chief Financial Officer

Tel: +612 9422 3000

Ambri Limited is developing the SensiDx™ System to deliver accurate, quantifiable results in less than five minutes in point-of-care applications for the Critical Care market. The SensiDx™ System includes an analyzer and series of test specific disposable cartridges that contain biosensors based on Ambri's patented ICS (Ion Channel Switch) Technology. Further information regarding the Company and its technology is available on its web site (www.ambri.com).